Reaching People, Changing Lives

At Aurinia Pharmaceuticals, we’re developing and delivering innovative products to patients suffering from debilitating diseases such as lupus nephritis (LN).

How We’re Helping Patients

Latest News

March 20, 2017 • 12:00am EDT

Aurinia Closes US$173.1 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares

Read Press Release View All News

March 16, 2017 • 12:00am EDT

Aurinia Announces Presentation at 12th International Congress on SLE (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017)

Read Press Release View All News

March 14, 2017 • 12:00am EDT

Aurinia Prices US$150.5 Million Public Offering of Common Shares

Read Press Release View All News

Email Alerts

Stay informed and receive company updates straight to your inbox

Sign Up Today